Intracerebral and Subarachnoid Hemorrhage

Acute Intracerebral Hemorrhage: Assessment, Blood Pressure, and Reversal

Primary non-traumatic intracerebral hemorrhage (ICH) occurs when a cerebral blood vessel ruptures directly into the brain parenchyma, with chronic hypertension serving as the single most common etiology. The sudden presence of an expanding hematoma disrupts local neural tissue and drives up tissue pressure. Depending on the exact location and size of the hemorrhage, patients may present with sudden focal neurological deficits, severe headache, nausea, vomiting, or an acute decline in level of consciousness. Because these acute manifestations can perfectly mimic acute ischemic events, rapid imaging is mandatory. A non-contrast head CT is the initial imaging test to identify acute hemorrhage; an early ischemic stroke may not yet be visible on CT.

Limiting early hematoma expansion is a primary clinical priority in the emergency and critical care phases. In patients presenting with mild to moderate acute intracerebral hemorrhage and a systolic blood pressure between 150 and 220 mmHg, prescribed intravenous antihypertensives may be titrated toward 140 mmHg while maintaining systolic pressure strictly within the range of 130 to 150 mmHg. Bedside nurses must titrate infusions carefully to avoid overshooting the target, as lowering systolic blood pressure below 130 mmHg may be harmful. Nicardipine is commonly administered as a titrated intravenous infusion for smooth, continuous control, while labetalol may be given as intravenous boluses or as an infusion according to provider orders and local critical care protocols.

Coagulopathy significantly escalates the risk of ongoing hematoma expansion and catastrophic neurological decline. In anticoagulant-associated acute intracerebral hemorrhage, the bedside nurse must promptly identify the specific anticoagulant agent, notify the provider immediately, and administer ordered reversal treatments as soon as possible. For acute warfarin-associated hemorrhage, four-factor prothrombin complex concentrate combined with intravenous vitamin K represents the first-line treatment. For direct oral anticoagulants, idarucizumab is a specific monoclonal antibody fragment used to reverse dabigatran in patients facing life-threatening bleeding. For apixaban- or rivaroxaban-associated life-threatening ICH, promptly administer the provider-ordered reversal treatment under current local protocols; four-factor prothrombin complex concentrate is an option, and andexanet alfa is no longer marketed in the United States following its 2025 safety-related withdrawal. Heparin reversal follows distinct pathways: protamine sulfate reverses unfractionated heparin and provides partial reversal for low-molecular-weight heparin in life-threatening bleeding. For patients on antiplatelet therapy who are not undergoing surgery, routine platelet transfusions are not recommended.

Managing intracranial dynamics requires vigilant nursing assessment and physical positioning. When hemodynamically tolerated, the nurse should elevate the head of the bed about 30 degrees and maintain neutral, midline neck alignment. This simple physical alignment optimizes internal jugular venous drainage and mitigates increases in intracranial pressure. When patients exhibit signs of symptomatic intracranial hypertension, hyperosmolar therapy with prescribed hypertonic saline or mannitol should be administered, followed by close monitoring of neurological responses, serum electrolytes, and fluid status. Routine prophylactic hyperosmolar therapy in the absence of symptomatic intracranial hypertension is not established.